Matricelf technology enables the production of autologous engineered tissue composed of scaffold and cells derived from patients biopsy.
The platform showed remarkable pre-clinical results for several medical conditions.
For its first clinical application, Matricelf focuses on spinal cord implants for patients suffering from traumatic Spinal Cord Injuries and plans to conduct its first human clinical trial for Acute Spinal Cord Injury (SCI) in 2024.
